Frequency of Epidermal Growth Factor Receptor Mutations among Filipino Patients with Non-small Cell Lung Carcinoma
Background. Epidermal Growth Factor Receptor (EGFR) mutation status has been shown to have a significant prognostic and predictive role in the management of Non-small Cell Lung Carcinoma (NSCLC), significantly prolonging patients' survival. Thus, EGFR mutational analysis before initiation of treatment is now recommended in several clinical practice guidelines. Although EGFR mutation testing in NSCLC has been a part of clinical care in the Philippines, there is little data on the EGFR mutation spectrum among Filipinos.
Objective. This study aims to determine the frequency of EGFR mutations among Filipino population diagnosed with NSCLC in a private tertiary care setting.
Methodology. A total of 626 tissue samples (444 biopsies, 108 pleural/ascitic fluids, 74 excision/resection), during a 15-month period (January 2015-March 2016) were assessed for the known EGFR driver mutations (exons 18, 19, 20, 21) using the Roche EGFR protocol with the Cobas Quantitative Real Time PCR. Macrodissection was performed as necessary. Available patient demographics were recorded. Statistical analyses were performed using the Fisher's exact test.
Results. In this study, we report the largest EGFR mutation profiling data among Filipino patients with NSCLC, which showed an overall 49.4 % EGFR mutation rate. The mutation rates according to histologic types, were as follows: adenocarcinoma (49.9 %, n=287/575), squamous cell carcinoma (3.5%, n=9/26), NSCLC NOS (50 %, n=10/20), adenosquamous cell carcinoma (66.7 %, n=2/3), and adenocarcinoma with neuroendocrine features (50%, n=1/2). Consistent with the literature, we found a significant higher incidence of EGFR mutation among women than men (60.2% vs 39.8%). With regards to individual mutation types, the most common mutations detected were deletions in exon 19 (54.7 %, n=168), followed by L858R point mutation in exon 21 (27.4 %, n=84).
Conclusion. The incidence of EGFR mutations in NSCLC varies across different ethnicity. In previous reports, the frequency of EGFR mutations is approximately 30% (with a range of 22.2% to 64.2%) among the Asian population compared with 20% among the white population. In the Philippines, the incidence of EGFR mutations is sparsely explored. Here we report the largest EGFR mutation profiling data among Filipinos with NSCLC in a tertiary care setting, with a frequency of 49.4%. This prevalence is almost similar to those reported in Asia. EGFR is differentially mutated among NSCLC patients with different gender, as women have significantly higher incidence than men. Hence, this study establishes relevance of routine EGFR mutation testing for all NSCLC patients as part of initial workup at diagnosis and underscores the significant role of EGFR inhibitors as a treatment option among Filipino population.
Ferlay JSH, Bray F, Forman D, Mathers C, and Parkin DM. GLOBOCAN 2012, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 (Internet). Lyon, France: International Agency for Research on Cancer.
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311(7010):899–909. PMID: 7580546. PMCID: PMC2550915.
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39. PMID: 15118073. https://doi.org/10.1056/NEJMoa040938.
Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500. PMID: 15118125. https://doi.org/10.1126/science.1099314.
Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor- related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;9(3):183–232. PMID: 7612182.
Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–8. PMID: 22370314. https://doi.org/10.1200/JCO.2011.36.8456.
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362(25):2380–8. PMID: 20573926. https://doi.org/10.1056/NEJMoa0909530.
Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101(36):13306–11. PMID: 15329413. PMCID: PMC516528. https://doi.org/10.1073/pnas.0405220101.
Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179–86.
D’Addario G, Felip E,; ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2): ii39–40. PMID: 18456762. https://doi.org/10.1093/annonc/mdn081.
Kawaguchi T, Matsumura A, Fukai S, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol. 2010;5(7):1001–10. PMID: 20526205. https://doi.org/10.1097/JTO.0b013e3181e2f607.
Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67. PMID: 19692684. https://doi.org/10.1056/NEJMoa0904554.
Yu JY, Yu SF, Wang SH, et al. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21. Chin J Cancer. 2016; 35:30. PMID: 27001083. PMCID: PMC4802875. https://doi.org/10.1186/s40880-016-0086-2.
Romanidou O, Landi L, Cappuzzo F, Califano R. Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Ther Adv Med Oncol. 2016;8(3):176–87. PMID: 27239236. PMCID: PMC4872250. https://doi.org/10.1177/1758834016631531/.
Cappuzzo F. Overcoming EGFR-TKI Resistance. Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Switzerland: Adis-Springer, 2015. https://doi.org/10.1007/978-3-319-20741-4_4.
Jänne PA, Yang JC, Kim DW. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–99. PMID: 25923549. https://doi.org/10.1056/NEJMoa1411817.
Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154 -62. PMID: 24419411. PMCID: PMC4132036. https://doi.org/10.1097/JTO.0000000000000033.
Yang PC, Shi Y, Au JS, et al. Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with advanced lung adenocarcinoma (PIONEER). J Clin Oncol. 2012;30. http://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.1534.
Heralde FI, Barzaga MT, Tan-Liu N, Bernal S. EGFR mutation profile of NSCLC patients tested at the Lung Center of the Philippines. J Thorac Oncol. 2017;12(11):S2257-8. https://doi.org/10.1016/j.jtho.2017.09.1585.
Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11(8):2879–82. PMID: 15837736. https://doi.org/10.1158/1078-0432.CCR-04-2029.
Li M, Zhang Q, Liu L, et al. The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China. Neoplasma. 2011;58(1):74–81. PMID: 21067269.
Sun MH, Yang F, Shen L, et al. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types]. Zhonghua Bing Li Xue Za Zhi, 2011;40(10):655–9. PMID: 22321541.
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. PMID: 19692680. https://doi.org/10.1056/NEJMoa0810699.
Copyright (c) 2018 Philippine Journal of Pathology
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Philippine Journal of Pathology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on works made open access at http://philippinejournalofpathology.org